Drug.givosirangivosiran will increase the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling.glasdegibolanzapine and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.goserelinolanzapine and goserelin both increase QTc interval. Avoid or Use Alternate Drug.histrelinolanzapine and histrelin both increase QTc interval. Avoid or Use Alternate Drug.hydrocodonehydrocodone, olanzapine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydroxychloroquine sulfatehydroxychloroquine sulfate and olanzapine both increase QTc interval. Avoid or Use Alternate Drug.ibutilideolanzapine and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.iloperidoneolanzapine and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.inotuzumabolanzapine and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug.isofluraneisoflurane and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesivosidenibivosidenib and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.lefamulinlefamulin and olanzapine both increase QTc interval. Avoid or Use Alternate Drug.leniolisibleniolisib will increase the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid leniolisib with CYP1A2 substrates that have a narrow therapeutic indexlenvatinibolanzapine and lenvatinib both increase QTc interval. Avoid or Use Alternate Drug.leuprolideolanzapine and leuprolide both increase QTc interval. Avoid or Use Alternate Drug.levodopaolanzapine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.levodopa inhaledolanzapine decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Atypical (2nd generation) antipsychotics inhibit dopamine D2 receptors in varying degrees (clozapine and quetiapine are lower risk). .lisurideolanzapine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.lonafarnibolanzapine will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.lopinavirolanzapine and lopinavir both increase QTc interval. Avoid or Use Alternate Drug.macimorelinmacimorelin and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.maprotilineolanzapine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.mefloquinemefloquine increases toxicity of olanzapine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.methadoneolanzapine and methadone both increase QTc interval. Avoid or Use Alternate Drug.methyldopaolanzapine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.metoclopramide intranasalolanzapine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.olanzapine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.midostaurinolanzapine and midostaurin both increase QTc interval. Avoid or Use Alternate Drug.mobocertinibmobocertinib and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.moxifloxacinolanzapine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.olopatadine intranasalolanzapine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. ondansetronolanzapine and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.oxaliplatinolanzapine and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug.oxaliplatin and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancespaliperidoneolanzapine and paliperidone both increase QTc interval. Avoid or Use Alternate Drug.panobinostatolanzapine and panobinostat both increase QTc interval. Avoid or Use Alternate Drug.paroxetineolanzapine and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.pazopanibolanzapine and pazopanib both increase QTc interval. Avoid or Use Alternate Drug.pefloxacinpefloxacin will increase the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.pentamidineolanzapine and pentamidine both increase QTc interval. Avoid or Use Alternate Drug.pimavanserinolanzapine and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug.pimozideolanzapine and pimozide both increase QTc interval. Contraindicated.pitolisantolanzapine and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.ponesimodolanzapine and ponesimod both increase QTc interval. Avoid or Use Alternate Drug.pramipexoleolanzapine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.procainamideolanzapine and procainamide both increase QTc interval. Avoid or Use Alternate Drug.propafenoneolanzapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.quetiapineolanzapine and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.quinidineolanzapine and quinidine both increase QTc interval. Avoid or Use Alternate Drug.ranolazineolanzapine and ranolazine both increase QTc interval. Avoid or Use Alternate Drug.ribociclibribociclib increases toxicity of olanzapine by QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances.ropiniroleolanzapine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamideolanzapine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.saquinavirolanzapine and saquinavir both increase QTc interval. Avoid or Use Alternate Drug.selinexorselinexor, olanzapine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sevofluranesevoflurane and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancessiponimodolanzapine will increase the level or effect of siponimod by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with drugs that cause moderate CYP2C9 AND a moderate or strong CYP3A4 inhibition is not recommended. Caution if siponimod coadministered with moderate CYP2C9 inhibitors alone.olanzapine and siponimod both increase QTc interval. Avoid or Use Alternate Drug.sodium oxybateolanzapine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sotalololanzapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.sufentanil SLsufentanil SL, olanzapine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tetrabenazineolanzapine and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug.thiothixeneolanzapine and thiothixene both increase QTc interval. Avoid or Use Alternate Drug.toremifeneolanzapine and toremifene both increase QTc interval. Avoid or Use Alternate Drug.trazodoneolanzapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.triptorelinolanzapine and triptorelin both increase QTc interval. Avoid or Use Alternate Drug.umeclidinium bromide/vilanterol inhaledolanzapine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vandetanibolanzapine and vandetanib both increase QTc interval. Avoid or Use Alternate Drug.vemurafenibolanzapine and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug.vilanterol/fluticasone furoate inhaledolanzapine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.ziprasidoneolanzapine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (383)abobotulinumtoxinAabobotulinumtoxinA increases effects of olanzapine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.acarboseolanzapine, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.aclidiniumaclidinium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.aclidinium decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineacrivastine and olanzapine both increase sedation. Use Caution/Monitor.albiglutideolanzapine, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.albuterololanzapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.albuterol and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesalfentanilalfentanil and olanzapine both increase sedation. Use Caution/Monitor.alfuzosinolanzapine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesalmotriptanalmotriptan, olanzapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).alprazolamalprazolam and olanzapine both increase sedation. Use Caution/Monitor.amifostineamifostine, olanzapine. Either increases effects of the other by anti-hypertensive channel blocking. Use Caution/Monitor. Due to its alpha adrenergic antagonism, atypical antipsychotic agents has the potential to enhance the effect of certain antihypertensive agents. Monitor blood pressure and adjust dose accordingly.amitriptylineolanzapine and amitriptyline both increase sedation. Use Caution/Monitor.olanzapine and amitriptyline both increase QTc interval. Use Caution/Monitor.amobarbitalamobarbital will decrease the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.amobarbital and olanzapine both increase sedation. Use Caution/Monitor.amoxapineolanzapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.olanzapine and amoxapine both increase sedation. Use Caution/Monitor.olanzapine and amoxapine both increase QTc interval. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.anticholinergic/sedative combos decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.apomorphineolanzapine and apomorphine both increase sedation. Use Caution/Monitor.arformoterololanzapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arformoterol and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesaripiprazolearipiprazole and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and olanzapine both increase sedation. Use Caution/Monitor.aripiprazole and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesarmodafinilarmodafinil will decrease the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.olanzapine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.asenapineasenapine and olanzapine both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case